FDA-approved digital health tools are software, AI systems, wearables, and apps that meet FDA safety and effectiveness standards. As of 2026, the FDA has cleared over 1,300 AI-enabled medical devices.
These tools cover diagnostics, chronic disease management, mental health, and remote monitoring, changing how patients receive care every day.
● The FDA has authorized over 1,300 AI-enabled medical devices as of 2025-2026.
● AI in radiology accounts for more than 75% of all FDA-authorized AI medical devices.
● Digital therapeutics are FDA-regulated software tools that treat conditions like depression, ADHD, and insomnia.
● Software as a Medical Device (SaMD) is the official FDA category for health software that functions like a medical device.
● The FDA Digital Health Center of Excellence guides the review and approval of new digital health technologies.
A radiologist in rural Montana doesn’t need to wait three days for a specialist to review a chest X-ray anymore. An AI tool does the preliminary read in seconds, flagged, categorized, and ready for physician confirmation. That’s one small example of what FDA-approved digital health tools are doing across American healthcare in 2026.
The shift is real and it’s accelerating. From AI that detects diabetic eye disease to apps that treat insomnia without sleeping pills, the FDA has been building a regulatory framework that keeps pace with technology. This article covers 10 of the most important FDA-approved digital health tools today, what they are, what they do, and why they matter to patients and providers.
What are FDA-Approved Digital Health Tools?
FDA-approved digital health tools are software systems, mobile apps, AI algorithms, and connected medical devices that have gone through an FDA review process and received authorization to be marketed in the United States. They include everything from wearable heart monitors to clinical AI that reads medical scans.
The FDA defines digital health broadly, covering mobile health apps, wearable devices, telehealth platforms, Software as a Medical Device (SaMD), and AI-enabled diagnostic tools. What they all share is a review process designed to confirm they work as intended and won’t put patients at risk.
Digital health products range widely in complexity and clinical purpose. A Fitbit-style wellness tracker sits at one end of the spectrum. A machine learning system that identifies early-stage lung cancer from a CT scan sits at the other.
The FDA draws a clear line between general wellness tools and tools that function as medical devices, and only the latter go through formal FDA review.
How Does FDA Approval Work for Digital Health? (Simplified)
Most FDA-approved digital health tools go through one of three pathways. Understanding them helps you know how much review a tool has actually received.
This is the most common pathway for digital health devices. A company submits evidence that its new tool is substantially equivalent to a legally marketed predicate device. It’s faster than full approval, but it still requires real clinical and safety data. Most AI diagnostic tools and SaMD examples reach the market through 510(k).
When a digital health tool has no clear predicate, meaning it’s genuinely new, companies can apply for De Novo classification. The FDA uses this pathway to develop new device categories while creating regulations for those devices. Many first-of-kind AI medical devices FDA approved in recent years went through De Novo.
PMA is the most rigorous pathway, reserved for high-risk devices. It requires clinical trials and extensive evidence. Some advanced AI systems for life-critical decisions go through PMA, though most digital health tools land in lower-risk categories.
Knowing which pathway a tool used helps patients and providers assess the depth of FDA review behind any digital health technologies FDA guidance covers.
10 FDA-Approved Digital Health Tools in 2026
Here are ten of the most clinically significant FDA-approved digital health tools available today, spanning AI, wearables, SaMD, and digital therapeutics.
1. IDx-DR (Now Autonomous AI for Diabetic Retinopathy)
Category: AI Medical Device / SaMD
IDx-DR was the first FDA-authorized autonomous AI diagnostic system, meaning it makes a clinical recommendation without a physician reviewing the image first. It analyzes retinal photographs and identifies diabetic retinopathy, a leading cause of blindness in adults with diabetes. Primary care offices can now screen patients without referring them to an ophthalmologist first, which matters enormously in underserved areas. This is one of the most cited AI medical devices examples in the FDA’s digital health history.
Category: FDA Digital Health Device / Wearable
Apple received FDA clearance for the ECG app on Apple Watch Series 4, and subsequent models have maintained that authorization. The app detects atrial fibrillation, an irregular heart rhythm that significantly raises stroke risk, directly from the wrist. Patients can run a 30-second ECG themselves and share the PDF with their physician.
Millions of Americans wear one daily, making this one of the most widely used FDA digital health devices list entries in consumer health history. Real-world data has already shown it catching AFib in people who had no prior symptoms.
3. Dario Blood Glucose Monitoring System
Category: FDA-Approved Digital Health Tool / Connected Device
Dario’s platform combines a smartphone-connected glucose meter with a digital health app that tracks readings, food logs, activity, and medication. The FDA cleared the monitoring device component, making it one of the more complete FDA-approved digital health tools for diabetes management.
For the 38 million Americans managing diabetes, tools like Dario reduce the friction of daily self-monitoring and connect patients to their care teams with real-time data.
Category: Digital Therapeutics FDA Authorized / SaMD
EndeavorRx is a prescription video game, and that sentence is entirely serious. Developed by Akili Interactive, it received FDA De Novo authorization in 2020 as a treatment for ADHD in children ages 8-12. Players navigate an obstacle course that trains attention systems in the brain. Clinical trials showed measurable improvement in attention function.
It’s one of the most recognizable entries on any FDA approved digital therapeutics list and a landmark moment for the digital therapeutics FDA category. It requires a prescription and works alongside other treatments.
Category: Digital Therapeutics FDA Authorized / Prescription App
Somryst is an FDA-authorized prescription digital therapeutic for chronic insomnia in adults. Built on cognitive behavioral therapy for insomnia (CBT-I), which research consistently shows outperforms sleep medications for long-term outcomes, Somryst delivers a nine-week structured program through a smartphone app.
A physician prescribes it. The patient works through sleep restriction protocols and cognitive restructuring exercises on their own time. For the 30% of American adults with chronic insomnia, this kind of digital therapeutics FDA approach offers a science-backed alternative with fewer side effects than pharmacological options.
6. Viz.ai Stroke Detection Platform
Category: AI Medical Device FDA Approved / Clinical Decision Support
Viz.ai’s platform uses an FDA-cleared AI algorithm to analyze CT scans in real time, detect signs of large vessel occlusion stroke, and immediately alert the neurology team, often before the radiologist has finished reviewing the scan. In stroke care, every minute without intervention costs brain function.
Viz.ai is deployed in hundreds of hospitals across the US and has been credited with reducing door-to-treatment time significantly. It sits among the most impactful AI medical devices FDA approved for emergency medicine and appears on the FDA-approved AI medical device list.
7. Contessa Health Remote Monitoring Platform
Category: Remote Patient Monitoring / FDA Digital Health Technologies
Remote patient monitoring (RPM) platforms allow clinicians to track patients’ vital signs from home rather than in a clinical setting. FDA digital health technologies in the RPM space have expanded rapidly since the pandemic accelerated telehealth adoption.
These platforms monitor heart rate, blood pressure, oxygen saturation, weight, and glucose, sending readings directly to care teams who can intervene before a patient deteriorates to the point of needing an ER visit. For patients managing heart failure or COPD, this kind of continuous visibility has measurably reduced hospitalizations.
8. BriefCase (Paige AI): AI Pathology
Category: AI Medical Device FDA Approved / Diagnostics
Paige AI received FDA authorization for its prostate cancer detection algorithm, the first AI pathology product ever to receive FDA De Novo authorization. The system analyzes digital pathology slides and flags areas suspicious for cancer, helping pathologists prioritize and catch cases they might otherwise miss under the pressure of high caseloads.
It’s a clear example of how the FDA-approved AI medical device list is expanding beyond radiology into pathology, which processes millions of cancer biopsies each year in the United States.
Category: Digital Therapeutics FDA / Prescription SaMD Examples
Pear Therapeutics’ reSET was the first prescription digital therapeutic to receive FDA authorization, cleared in 2017 for substance use disorder. reSET-O followed for opioid use disorder treatment.
Both apps deliver CBT-based therapy modules, collect patient-reported outcomes, and share adherence data with treatment providers. They are designed as adjuncts to outpatient treatment programs. The authorization of these products opened the door to what is now a growing FDA approved digital therapeutics list.
Though Pear faced business challenges in 2023, the products themselves remain significant milestones in digital health regulation.
10. Caption AI (Ultrasound Guidance)
Category: AI Medical Device / Point-of-Care Diagnostics
Caption AI received FDA clearance for its AI-assisted cardiac ultrasound guidance tool. It uses real-time AI to guide non-specialist clinicians, including nurses and primary care providers, in capturing diagnostic-quality echocardiograms. Cardiac ultrasound typically requires specialized training.
Caption AI makes it accessible at point-of-care settings and in rural clinics where a sonographer is unavailable. It’s a strong answer to the question of what is an FDA approved AI tool that directly expands access to diagnostic care.
Key Trends in FDA Digital Health for 2026
AI Is Dominating New Approvals
The FDA has authorized over 1,300 AI-enabled medical devices as of 2025–2026, with radiology accounting for the largest share, more than 75% of authorized AI medical devices touch imaging and diagnostics.
The pace of authorizations has accelerated each year since 2020. AI medical devices FDA approved in recent cycles span cardiology, dermatology, ophthalmology, and pathology, signaling that the technology is moving across every clinical specialty.
Digital Therapeutics Are Gaining Ground
Mental health digital therapeutics have seen particular growth. Conditions including depression, anxiety, PTSD, and substance use disorders now have FDA-regulated software treatment options.
The digital therapeutics FDA framework continues to evolve, with the FDA issuing updated guidance on Software as a Medical Device that gives developers clearer paths to authorization. The FDA Digital Health Center of Excellence has been central to coordinating these regulatory updates.
Remote Monitoring Has Become Standard of Care
Remote patient monitoring went from a niche service to a mainstream care model. CMS expanded reimbursement codes for RPM, driving adoption among physician practices and health systems.
FDA digital health devices designed for home use, connected blood pressure cuffs, pulse oximeters, CGMs, now feed data directly into electronic health records. The clinical evidence for RPM reducing hospitalizations in chronic disease management has grown substantially.
What are the Benefits of FDA-Approved Digital Health Tools?
● Clinical accuracy: FDA review requires evidence that a tool performs as claimed, reducing the chance patients receive misleading health information.
● Expanded access: AI diagnostic tools and RPM platforms bring specialist-level care to rural and underserved communities.
● Earlier detection: Tools like IDx-DR and Viz.ai catch conditions at earlier, more treatable stages than traditional care workflows allow.
● Cost reduction: Remote monitoring and digital therapeutics can reduce unnecessary ER visits, hospitalizations, and in-person specialist appointments.
● Patient engagement: Apps that track health data between appointments keep patients active in their own care rather than passive recipients.
What are the Challenges and Concerns?
FDA-approved digital health tools carry real clinical benefits, but the honest picture includes challenges worth understanding.
AI medical devices are only as good as the data they were trained on. Several studies have found that AI diagnostic systems perform less accurately on patients of color when training datasets skewed toward white patients.
The FDA has acknowledged algorithmic bias as a known challenge and has pushed manufacturers to include diverse datasets in validation studies. This remains an active area of regulatory concern.
Digital health products collect sensitive personal health data. FDA approval addresses clinical performance, it doesn’t guarantee HIPAA compliance or strong data security practices.
Patients using FDA health apps approved for clinical use should still read privacy policies and understand what data is shared with third parties, including insurers and advertisers.
The boundary between a general wellness app and an FDA-regulated medical device is still not always clear. Many health apps marketed directly to consumers sit in regulatory gray zones. The FDA issued updated digital health technologies FDA guidance to clarify these boundaries, but enforcement remains inconsistent.
A device that performs well in a controlled clinical trial may perform differently in real-world clinical environments, with older equipment, rushed workflows, or less-trained users. Post-market surveillance of FDA digital health devices is improving but remains less rigorous than pre-market review.
How are These Tools Changing Healthcare in Practice?
The clearest impact shows up in three areas: early detection, rural care access, and chronic disease management.
A 60-year-old woman in a rural clinic gets a retinal scan during her annual physical. The AI flags early diabetic retinopathy. Her primary care doctor orders a follow-up referral that day. Three years earlier, that finding would have waited for a specialist appointment, if she ever got one.
A patient with heart failure monitors his weight and blood pressure at home every morning. His care team’s RPM platform alerts them when his numbers trend the wrong way. They call him before he decompensates. He avoids hospitalization. His insurer saves $15,000. He doesn’t miss work.
A teenager prescribed EndeavorRx plays 25 minutes of AI-guided gameplay five days a week. Her attention scores improve over eight weeks. Her parents describe it as the first intervention that felt sustainable long-term. These are the practical outcomes behind the regulatory approvals, real patients, measurable results.
How to Check If a Digital Health Tool Is FDA Approved
The FDA maintains a publicly searchable database called the 510(k) Premarket Notification database, the De Novo database, and the PMA database, all accessible through the FDA’s website at fda.gov. You can search by product name, company, or device category.
For AI medical devices specifically, the FDA publishes an updated FDA-approved AI medical device list on its Digital Health Center of Excellence page. Searching “FDA Digital Health Center of Excellence” and navigating to the AI/ML-based Software as a Medical Device section gives you the most current information.
When evaluating any digital health product, look for the FDA clearance number (the K number for 510(k) devices), the indication for use statement, and whether the company has published clinical validation data.
What is the Future of FDA Digital Health?
The trajectory through 2026 and beyond points toward AI that doesn’t just flag findings but generates clinical recommendations with traceable reasoning. The FDA is actively developing frameworks for AI systems that learn and update continuously, a fundamentally different regulatory challenge than static software.
Personalized medicine will deepen the role of digital health tools. As genomic data, continuous biosensors, and AI models converge, physicians will have far more granular information about individual patients than any prior generation of medicine offered. The regulatory question becomes how to evaluate tools that adapt over time rather than performing a fixed function.
The FDA Digital Health Center of Excellence is central to navigating these questions. It works across FDA centers, coordinates with international regulators, and engages industry on pre-submission guidance. Watch for updated Software as a Medical Device guidance and new frameworks for AI transparency requirements in 2026 and 2027.
● There are over 1,300 FDA-authorized AI-enabled medical devices as of 2026, the number grows every month.
● FDA-approved digital health tools span AI diagnostics, prescription apps, wearable monitors, and mental health digital therapeutics
● Approval pathways, 510(k), De Novo, and PMA, determine the depth of FDA review any given tool has undergone.
● The FDA Digital Health Center of Excellence coordinates regulatory guidance for new digital health technologies.
● Real-world impact is measurable: earlier diagnoses, fewer hospitalizations, and broader access to specialist-level care.
FAQ: FDA-Approved Digital Health Tools
What digital health tools are FDA approved?
FDA-approved digital health tools include AI diagnostic systems (like IDx-DR and Viz.ai), prescription digital therapeutics (like EndeavorRx and Somryst), connected wearable devices (like the Apple Watch ECG), remote patient monitoring platforms, and clinical decision support software. The FDA digital health devices list covers hundreds of products across every major clinical specialty.
How many AI medical devices are FDA approved?
As of 2025–2026, the FDA has authorized over 1,300 AI-enabled medical devices. Radiology accounts for the majority, more than 75% of AI medical devices FDA approved touch imaging and diagnostics. The number has grown significantly each year since 2017. The FDA publishes an updated list on its Digital Health Center of Excellence page.
Some health apps are FDA-authorized, but many are not because they fall outside FDA’s regulatory scope. FDA health apps approved for clinical use typically function as Software as a Medical Device, meaning they are intended to diagnose, treat, or manage a medical condition. General wellness apps that track steps or sleep do not require FDA review. The distinction comes down to intended clinical use.
SaMD stands for Software as a Medical Device. It refers to software intended to be used for a medical purpose without being part of a physical hardware device. SaMD examples include AI algorithms that analyze medical images, apps that interpret ECG data, and prescription digital therapeutics that deliver cognitive behavioral therapy. The FDA regulates SaMD based on the risk level of the intended use.
How do I verify if a digital health tool is FDA approved?
You can verify FDA authorization by searching the FDA’s public device databases at fda.gov, the 510(k) database, the De Novo database, or the PMA database. For AI devices specifically, the FDA-approved AI medical device list is available through the Digital Health Center of Excellence. Look for the clearance number and indication for use to confirm what the device is actually authorized to do.
What is the FDA Digital Health Center of Excellence?
The FDA Digital Health Center of Excellence (DHCoE) is the FDA’s primary office for digital health policy, guidance, and regulatory oversight. It coordinates review of SaMD, AI-enabled devices, and digital therapeutics across FDA centers. It publishes the FDA approved digital therapeutics list, digital health guidance documents, and updates on the FDA-approved AI medical device list. It was established to help the agency keep pace with rapidly evolving digital health technologies.
